Levetiracetam-Induced Seizure Aggravation in Patients With Focal Cortical Dysplasia

摘要: Objectives The choice of antiepileptic drug is typically based on seizure type, and there no evidence for superior effectiveness or potential deterioration particular in specific etiologic subgroups. aim the study was to identify etiological factor(s) associated with increased risk aggravation levetiracetam (LEV). Methods A retrospective analysis 139 patients treated LEV performed. Seizure defined as a 100% greater increase seizures frequency, which occurred within 1 month introduction. Results Five who fulfilled selection criteria were identified. low doses (500-1000 mg) LEV. In addition frequency duration, 2 developed new types. Withdrawal resulted return background all patients. Four 5 have distinctive magnetic resonance imaging finding focal cortical dysplasia. No paradoxical effect detected idiopathic epilepsy group other types symptomatic epilepsies. Conclusions Our results suggest that may possibly induce exacerbation subset dysplasia-related epilepsy, although large studies are needed establish relation. Underlying causes could impact treatment because electroclinical semiology might be "final common pathway" different epileptogenic mechanisms diverse etiologies.